14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CBLI ranks #17191 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Cleveland BioLabs Stock Forecast NASDAQ:CBLI

$1.48 (7.25%)

Volume: 90k

Closed: Jan 25, 2022

Hollow Logo Score: -5.330

Cleveland BioLabs Stock Forecast

$1.48 (7.25%)

Volume: 90k

Closed: Jan 25, 2022

Score Hollow Logo -5.330

Cleveland BioLabs Company Profile

73 High Street

Buffalo NY 14203



Industry: Biotechnology

Sector: Healthcare

Cleveland BioLabs


Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate includes Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is used for the prevention of death from acute radiation syndrome, and is used as an oncology drug. The company is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. It has strategic partnerships with The Cleveland Clinic Foundation and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE